Revolutionizing Brain Cancer Treatment: A Non-Invasive Approach
Imagine a world where brain tumors, one of the most aggressive and deadly forms of cancer, could be treated without invasive procedures. Researchers at Washington University School of Medicine in St. Louis, in collaboration with scientists at Northwestern University, have developed a groundbreaking strategy to tackle glioblastoma, a rapidly advancing and almost always fatal brain cancer. Their innovative approach involves carefully designed nanostructures that can deliver potent cancer-fighting compounds directly to the brain through simple nasal drops.
In a recent study published in PNAS, the researchers demonstrated the effectiveness of this non-invasive treatment in mice with glioblastoma. By stimulating the brain's immune system, they were able to successfully treat the cancer, offering a glimmer of hope for patients facing this devastating disease.
The Challenge of Glioblastoma Treatment
Glioblastoma, which develops from astrocytes, a type of brain cell, is the most common malignant brain tumor, affecting approximately three in every 100,000 people in the U.S. Its rapid progression and almost always fatal nature make it one of the most challenging cancers to treat. One of the primary obstacles is the difficulty of delivering effective medicine to the brain.
Alexander H. Stegh, PhD, a professor and vice chair of research in the WashU Medicine Taylor Family Department of Neurosurgery, and his team wanted to change this reality. They aimed to develop a non-invasive treatment that could activate the immune response to attack glioblastoma. Through their research, they discovered that precisely engineered nanostructures called spherical nucleic acids (SNAs) could safely and effectively activate powerful immune pathways within the brain.
Reactivating the Immune System with STING Pathway Nanomedicine
Glioblastoma is often referred to as a 'cold tumor' because it does not naturally provoke a strong immune response. Unlike 'hot tumors' that are more responsive to immunotherapies, glioblastoma tends to evade detection. Scientists have been exploring ways to stimulate the STING pathway, which activates immune defenses when cells detect foreign DNA.
Previous research had shown that drugs activating the STING pathway could prime the immune system to attack glioblastoma. However, these drugs degrade quickly and must be injected directly into the tumor for effectiveness. This invasive approach requires multiple doses, causing significant discomfort for patients.
Akanksha Mahajan, PhD, a postdoctoral research associate in Stegh's lab, proposed a novel solution. She suggested using spherical nucleic acid platforms to deliver these drugs in a non-invasive manner, minimizing the burden on patients already battling the disease.
Building Gold-Core Nanostructures for Nose-to-Brain Delivery
To address the challenge of delivering drugs to the brain, Stegh's group collaborated with Chad A. Mirkin, PhD, director of the International Institute for Nanotechnology and the Rathmann Professor of Chemistry at Northwestern University. Mirkin's expertise in developing spherical nucleic acids, which are nanoscale particles coated with DNA or RNA, proved invaluable.
Together, the teams designed a specialized version of spherical nucleic acids with gold nanoparticle cores and short DNA fragments that activate the STING pathway in targeted immune cells. The researchers then utilized the nasal passages as the entry point for these compounds, aiming to reach the brain.
Intranasal delivery for brain-targeted treatments has been studied before, but no nanoscale therapy had previously demonstrated the ability to activate immune responses against brain tumors using this route. This groundbreaking achievement marked the first time that immune cell activation in glioblastoma tumors was increased through nasal delivery of nanoscale therapeutics.
Tracking Nanodrops as They Travel to the Brain
The researchers took a meticulous approach to demonstrate both selective delivery to the brain and the proper activation of target immune cells. They added a molecular tag to the spherical nucleic acids that glowed under near-infrared light. After administering the nanodrops to mice with glioblastoma, they observed the particles traveling along the pathway of the main nerve connecting the facial region to the brain.
Once in the brain, the immune response triggered by the nanomedicine concentrated in specific immune cells within the tumor. Some activity was also detected in nearby lymph nodes. Crucially, the therapy did not spread widely throughout the body, reducing the likelihood of unwanted side effects.
Further examination revealed that immune cells in and around the tumor had activated the STING pathway, enabling them to mount a stronger attack against the cancer.
Combining Treatments for Tumor Eradication and Prevention of Recurrence
When the nanotherapy was combined with medicines that help activate T lymphocytes, another crucial type of immune cell, the two-dose treatment eliminated tumors in mice and produced long-lasting immunity that prevented the cancer from returning. These outcomes significantly outperformed those seen with current STING-targeting therapies.
Stegh emphasized that stimulating the STING pathway alone is unlikely to cure glioblastoma. The tumor employs various tactics to weaken or shut down the immune response. His group is exploring ways to incorporate additional immune-activating features into their nanostructures, potentially allowing multiple therapeutic targets to be addressed through a single treatment.
Stegh expressed optimism about the future of glioblastoma treatment, stating that this approach offers hope for safer, more effective treatments and marks a significant step toward clinical application. The study's findings open up exciting possibilities for improving the lives of patients affected by this devastating disease.
